Management of Dyspnea in Advanced Cancer: ASCO Guideline

Author:

Hui David1ORCID,Bohlke Kari2ORCID,Bao Ting3ORCID,Campbell Toby C.4,Coyne Patrick J.5,Currow David C.6ORCID,Gupta Arjun7ORCID,Leiser Aliza L.8,Mori Masanori9ORCID,Nava Stefano10,Reinke Lynn F.11ORCID,Roeland Eric J.12ORCID,Seigel Carole13,Walsh Declan14ORCID,Campbell Margaret L.15ORCID

Affiliation:

1. MD Anderson Cancer Center, Houston, TX

2. American Society of Clinical Oncology, Alexandria, VA

3. Memorial Sloan Kettering Cancer Center, New York, NY

4. University of Wisconsin-Madison, Madison, WI

5. Medical University of South Carolina, Charleston, SC

6. University of Technology Sydney, Sydney, Australia

7. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

8. Rutgers RWJ Cancer Institute of New Jersey, New Brunswick, NJ

9. Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan

10. IRCCS Azienda Ospedaliera University of Bologna, S. Orsola-Malpighi Hospital, Alma Mater University, Bologna, Italy

11. VA Puget Sound Health Care System, Seattle, WA

12. Massachusetts General Hospital Cancer Center, Boston, MA

13. Patient/family representative, Brookline, MA

14. Levine Cancer Institute, Charlotte, NC

15. Wayne State University, Detroit, MI

Abstract

PURPOSE To provide guidance on the clinical management of dyspnea in adult patients with advanced cancer. METHODS ASCO convened an Expert Panel to review the evidence and formulate recommendations. An Agency for Healthcare Research and Quality (AHRQ) systematic review provided the evidence base for nonpharmacologic and pharmacologic interventions to alleviate dyspnea. The review included randomized controlled trials (RCTs) and observational studies with a concurrent comparison group published through early May 2020. The ASCO Expert Panel also wished to address dyspnea assessment, management of underlying conditions, and palliative care referrals, and for these questions, an additional systematic review identified RCTs, systematic reviews, and guidelines published through July 2020. RESULTS The AHRQ systematic review included 48 RCTs and two retrospective cohort studies. Lung cancer and mesothelioma were the most commonly addressed types of cancer. Nonpharmacologic interventions such as fans provided some relief from breathlessness. Support for pharmacologic interventions was limited. A meta-analysis of specialty breathlessness services reported improvements in distress because of dyspnea. RECOMMENDATIONS A hierarchical approach to dyspnea management is recommended, beginning with dyspnea assessment, ascertainment and management of potentially reversible causes, and referral to an interdisciplinary palliative care team. Nonpharmacologic interventions that may be offered to relieve dyspnea include airflow interventions (eg, a fan directed at the cheek), standard supplemental oxygen for patients with hypoxemia, and other psychoeducational, self-management, or complementary approaches. For patients who derive inadequate relief from nonpharmacologic interventions, systemic opioids should be offered. Other pharmacologic interventions, such as corticosteroids and benzodiazepines, are also discussed. Additional information is available at www.asco.org/supportive-care-guidelines .

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3